Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for rapidly measuring mizoribine drug concentration

A technology for mizoribine and blood drug concentration, which is applied in the field of medical testing, can solve the problems of measurement accuracy, low precision, tedious and troublesome operation, and high analysis cost, and achieves a low cost, fast and accurate method, and low plasma consumption. Effect

Inactive Publication Date: 2008-07-23
THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIV
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] At present, there are few relevant reports at home and abroad about the determination methods of MZR in biological samples. The existing methods do not use the internal standard method for quantification, and the measurement accuracy and precision are low, and there is low sensitivity (the lowest limit of quantification is 0.1mg· L -1 ), cumbersome operation, low efficiency, high analysis cost and other defects, it is not suitable for routine therapeutic drug concentration monitoring

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for rapidly measuring mizoribine drug concentration
  • Method for rapidly measuring mizoribine drug concentration
  • Method for rapidly measuring mizoribine drug concentration

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] Chromatographic conditions

[0027] Chromatographic column: Hypersil BDS C18 (4.6×250mm, 5μm, Dalian Elite Company); mobile phase: 10mmol L -1 Potassium dihydrogen phosphate solution (containing perchloric acid 10mmol·L -1 , PH6.0 6.5); flow rate: 1.5mL min -1 ; Column temperature: room temperature; Detection wavelength: 280nm.

[0028] Plasma sample pretreatment

[0029] Take 200 μL of plasma sample, add 20 mg·L -1 Cytarabine 20μL, add 20μL distilled water, vortex mix for 30s, add 0.1mol L -1 Perchloric acid, vortex mixing for 1min, 10000r·min -1 After centrifugation for 5 min, 20 μL of the supernatant was taken for injection. The internal standard method was quantified by the peak area ratio of MZR and cytarabine.

[0030] Exclusive

[0031] Blood samples from 10 kidney transplant patients who did not take MZR were taken from different sources, and measured according to the above sample pretreatment and measurement methods. The results showed that no endogenou...

Embodiment 2

[0040] Chromatographic conditions

[0041] Chromatographic column: Hypersil BDS C18 (4.6×250mm, 5μm, Dalian Elite Company); mobile phase: 10mmol L -1 Potassium dihydrogen phosphate solution (containing 20mmol·L perchloric acid -1 , PH6.0-6.5); flow rate: 1.5mL min -1 ; Column temperature: room temperature; Detection wavelength: 280nm.

[0042] Plasma sample pretreatment

[0043] Take 200 μL of plasma sample, add 20 mg·L -1 Cytarabine 20 μL, add 20 μL distilled water, vortex mix for 30 seconds, add 0.25mol L -1 Perchloric acid, vortex mixing for 1min, 10000r·min -1 After centrifugation for 5 min, 20 μL of the supernatant was taken for injection. The internal standard method was quantified by the peak area ratio of MZR and cytarabine.

[0044] Exclusive

[0045] Blood samples from 10 kidney transplant patients who did not take MZR were taken from different sources, and measured according to the above sample pretreatment and measurement methods. The results showed that no...

Embodiment 3

[0051] Chromatographic conditions

[0052] Chromatographic column: Hypersil BDS C18 (4.6×250mm, 5μm, Dalian Elite Company); mobile phase: 10mmol L -1 Potassium dihydrogen phosphate solution (containing 30mmol·L perchloric acid -1 , PH6.0-6.5); flow rate: 1.5mL min -1 ; Column temperature: room temperature; Detection wavelength: 280nm.

[0053] Plasma sample pretreatment

[0054] Take 200 μL of plasma sample, add 20 mg·L -1 Cytarabine 20 μL, add 20 μL distilled water, vortex mix for 30 seconds, add 0.5mol L -1 Perchloric acid, vortex mixing for 1min, 10000r·min -1 After centrifugation for 5 min, 20 μL of the supernatant was taken for injection. The internal standard method was quantified by the peak area ratio of MZR and cytarabine.

[0055] Exclusive

[0056] Blood samples from 10 kidney transplant patients who did not take MZR were taken from different sources, and measured according to the above sample pretreatment and measurement methods. The results showed that no ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an analysis measurement method of internal drug, in particular to a method for quickly measuring mizonbine density of human blood plasma, which comprises adding sample into an interior label, after protein deposition pretreatment, isocratically eluting under water-type flow phase condition, separating via a chromatographic column, and detecting via an ultrasonic detector. The invention has low sample consumption, simple, quick and sensitive pretreatment, which not demands expensive device and organic solvent, with wide application, low environment pollution, low cost and the application for detecting clinical general blood drug density.

Description

technical field [0001] The invention belongs to the field of medical examination and relates to an analysis and determination method of drugs in vivo, in particular to a method for rapidly determining the concentration of mizoribine in human blood plasma. Background technique [0002] Mizoribine (MZR) is a purine nucleoside synthesis inhibitor, which can specifically inhibit the rapid growth of lymphocytes, thereby producing immunosuppressive effects. In recent years, it has been clinically used to suppress rejection during kidney transplantation, and is also used to treat autoimmune diseases such as lupus nephritis, rheumatoid arthritis and nephrotic syndrome. The pharmacokinetics of this drug varies greatly among individuals, and clinically, blood drug concentration monitoring is required to adjust the individualized dosage regimen. [0003] At present, there are few relevant reports at home and abroad about the determination methods of MZR in biological samples. The exis...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N30/02G01N33/48
Inventor 陈孝任斌张志豪王长希
Owner THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com